The latest closing stock price for ProQR Therapeutics as of March 29, 2021 is 7.83. The all-time high ProQR Therapeutics stock closing price was 24.99 on March 10, 2015. The ProQR Therapeutics 52-week high stock price is 9.46, which is 20.8% above the current share price.

ProQR Therapeutics NV (NASDAQ:PRQR) ProQR Therapeutics NV. 6.26. Delayed Data. As of Apr 09. -0.26 / -3.99%. Today’s Change. 3.40. Today ||| 52-Week Range.

Apr 9, 2021 Current quotes, charts, news, historical data, and analysis for Proqr Proqr Therapeutics NV Ordina Stock Weekly Stock Market Forecast Proqr Therapeutics (NQ: PRQR ). 9.220 USD +3.540 (+38.39%). Official Closing Price 4:36:04 PM EDT, Mar 25, 2021 Add to My Watchlist · Quote · Overview Latest ProQR Therapeutics NV (PRQR:NMQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. This is the initial public offering of the ordinary shares of ProQR Therapeutics B.V. We share price and volume fluctuations attributable to inconsistent trading Mar 24, 2021 Based on this decision, in 2020 stock options with an exercise price of € 8.82 have been granted to Daniel de Boer with respect to 395,561 Proqr Therapeutics N.V. (PRQR) SEC Filing 20-F Annual report for the fiscal year share price and volume fluctuations attributable to inconsistent trading Get ProQR Therapeutics NV (PRQR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Dec 17, 2019 ProQR Therapeutics (Nasdaq: PRQR) is developing three drugs that each target a rare childhood disease. If all three drugs succeed, ProQR In addition, the average price target of $4 provides an uptung potential to 304%. ( See Chip Rank's AZRX Stock Analysis) ProQR (PRQR) ProQR is a Jan 28, 2021 ProQR Therapeutics; Editas Medicine; Nobelpharma Co., Ltd profitable opportunities to the market players in the forecast period of 2021 to Averaged Moderna stock price for month 97.

Proqr stock forecast

GlobeNewswire. May-07-20 08:55AM : Find out how ProQR’s stock is trading now and in the past. Real time share price and trading volume information and an investor calculator is available. ProQR Therapeutics NV Stock Dividend Yield & Dates Add to Watchlist. Overview Forecast Earnings Dividend.

2021-04-12 Covid-19 is delaying ProQR’s pivotal Based on these assumptions, we calculated a sales forecast based on this model. Sales expectation ($, in millions leading to a surge in stock price.

Intellia Therapeutics, Inc. (NTLA) Stock: A Biotech Stock NTLA Stock Forecast, Price Intellia Therapeutics, Inc. - nyheter om bolaget - Dagens Industri; ProQR

PRQR Stock Summary. PRQR's price/sales ratio is 30.33; that's higher than the P/S ratio of 92.29% of US stocks. With a year-over-year growth in debt of 165.83%, ProQR Therapeutics NV's debt growth rate surpasses 92.83% of about US stocks.

ProQR (PRQR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

This suggests a possible upside of 424.3% from the stock's current price. ProQR Therapeutics Stock Forecast, PRQR stock price prediction. Price target in 14 days: 8.715 USD. The best long-term & short-term ProQR Therapeutics share price prognosis for 2021, 2022, 2023, 2024, 2025, 2026 with daily PRQR exchange price projections: monthly and daily opening, closing, maximum and minimum stock price outlook with smart technical analysis ProQR Therapeutics NV (NASDAQ:PRQR) ProQR Therapeutics NV. 6.26. Delayed Data. As of Apr 09.

With a year-over-year growth in debt of 165.83%, ProQR Therapeutics NV's debt growth rate surpasses 92.83% of about US stocks. Find the latest ProQR Therapeutics N.V. (PRQR) stock quote, history, news and other vital information to help you with your stock trading and investing. 2021-04-14 2021-04-14 ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Its product pipeline include Sepofarsen, QR-421a, QR-1123, and QR-504a. ProQR Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRQR will outperform the market and that investors should add to their positions of ProQR Therapeutics. View the latest ratings for PRQR.
Niall ferguson ayaan hirsi ali

Earnings estimates and surprises for Proqr Therapeutics (PRQR) are an important tool used to evaluate the company's overall strength and value of the stock. 2021-03-25 ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for Find out how ProQR’s stock is trading now and in the past. Real time share price and trading volume information and an investor calculator is available.

ProQR Therapeutics NV. 's earnings in 2021 is -$63,759,551.. On average, 3 Wall Street analysts forecast PRQR's earnings for 2021 to be $-44,964,325, with the lowest PRQR earnings forecast at $-53,644,652, and the highest PRQR earnings forecast at $-38,095,477.

PRQR's price/sales ratio is 30.33; that's higher than the P/S ratio of 92.29% of US stocks. With a year-over-year growth in debt of 165.83%, ProQR Therapeutics NV's debt growth rate surpasses 92.83% of about US stocks. Find the latest ProQR Therapeutics N.V. (PRQR) stock quote, history, news and other vital information to help you with your stock trading and investing. 2021-04-14 2021-04-14 ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa.

Albus dumbledore actor

Intellia Therapeutics, Inc. (NTLA) Stock: A Biotech Stock NTLA Stock Forecast, Price Intellia Therapeutics, Inc. - nyheter om bolaget - Dagens Industri; ProQR

3.40. Today ||| 52-Week Range. Proqr Therapeutics Stock Forecast is based on your current time horizon. Investors can use this forecasting interface to forecast Proqr Therapeutics historical stock prices and determine the direction of Proqr Therapeutics's future trends based on various well-known forecasting models. Based on 3 analysts offering 12 month price targets for ProQR in the last 3 months. The average price target is $35.00 with a high forecast of $35.00 and a low forecast of $35.00.

2020-08-29 · Stock analysis for ProQR Therapeutics NV (PRQR:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

ProQR Therapeutics NASDAQ Updated Mar 25, 2021 11:59 PM. PRQR 9.22 3.54 (62.32%). Post-Market 0.11 (1.19%) The latest closing stock price for ProQR Therapeutics as of March 29, 2021 is 7.83. The all-time high ProQR Therapeutics stock closing price was 24.99 on March 10, 2015. The ProQR Therapeutics 52-week high stock price is 9.46, which is 20.8% above the current share price.

3.40. Today ||| 52-Week Range. Proqr Therapeutics Stock Forecast is based on your current time horizon.